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article under the CC BY-NC-ND licenseAbstract We report a case of a 35-year-old lady who presented with Cushingoid features and
associated raised urinary metanephrine. The patient underwent open adrenelectomy. Histo-
pathological examination revealed adreno-cortical carcinoma with microscopic lymphovascu-
lar invasion. Postoperative period was uneventful and is on follow-up for the last one year
and is doing well.
ª 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Adrenal carcinoma is an aggressive malignant neoplasia
arising from the adrenal cortex with poor prognosis. It
represents 0.02% of all neoplasia. Global incidence is 0.5e2
per every 1,000,000 inhabitants [1]. The age distribution is
reported as bimodal with a first peak in childhood and a
second higher peak in the fourth and fifth decade [2,3].
Women are more often affected than men in the ratio of
1.5 [3e5]. Tumors are classified as functioning when theyoo.co.in (P.K. Bagchi).
f Shanghai Medical Associa-
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(http://creativecommons.org/liare associated with endocrine manifestations or elevated
hormone levels. Cushing’s syndrome is due to hyper-
cortisolism while pheochromocytoma is a catecholamine
secreting tumor of the adrenal medulla or extra adrenal
sites. Adrenal carcinoma accounts for approximately 33%e
53% of cases of Cushing’s syndrome [6,7]. However, it is
rare for adrenocortical carcinoma to present clinically as
pheochromocytoma. We report a case of a 35-year-old lady
who presented with Cushingoid features and associated
raised urinary metanephrine.
2. Description of case
A 35 years old female presented with the chief complaint of
altered menstrual symptoms for the last 10 months. Shen and hosting by Elsevier (Singapore) Pte Ltd. This is an open access
censes/by-nc-nd/4.0/).
Figure 2 Intraoperative view.
Giant adrenal tumor presenting as Cushing’s syndrome and pheochromocytoma 183also complained of dull aching pain in the left flank without
any radiation or shifting and frequent episodes of general-
ized headache, palpitation and anxiety for the last 5
months. The palpitation was abrupt in onset and lasts for
about 30 min to 1 h, occurs 4e5 times per week, and was
associated with day-to-day household activities. The pa-
tient gradually developed swelling of both her lower limbs
and she had great difficulty in getting up from the squatting
position. On clinical examination, she was found to have
chemosis with swelling of eye lids, flushing of face,
increased facial hair distribution, hypertension, centripetal
obesity, and bilateral pedal edema. On examination of her
abdomen, a firm mass at left hypochondriac region approx
10 cm 7 cm in size was felt with smooth surface and well
defined margins, and fingers could not be insinuated below
the costal margin. Laboratory work-ups including full blood
count, renal function tests, serum electrolytes, and liver
function tests were within normal limit. Serum cortisol
[morning e 31.79 mg/dL (normal: 4.30e22.40), evening e
32.73 mg/dL (normal: 3.09e16.66)] and 24 h-urine norepi-
nephrine e 117.21 mg per 24 h (normal: 12.10e85.50),
dopamine e 592.82 mg per 24 h (normal: 52.00e480.00)
levels were raised. CT scan revealed a 18.3 cm  12
cm  16 cm left sided hypervascular retroperitoneal mass
without any invasion of the adjacent organs and showing
focus of calcification and microscopic fat component
(Fig. 1). Preoperatively, the patient was placed on a
blockers (Tab. Prazosin 5 mg at bedtime) for the effective
management of blood pressure. After effective stabiliza-
tion of blood pressure, she was taken up for exploration. On
exploration of abdomen, a left adrenal mass of approx 21
cm  12 cm  8 cm in size, fixed to left kidney with evi-
dence of local invasion was found (Fig. 2). The left adrenal
vein was isolated and suture ligated before attempts were
made to dissect out the adrenal mass. The mass weighed
380 g (Fig. 3). The capsule of the mass was intact with
hemorrhagic and necrotic areas seen at places on cross
section. Intraoperatively there were fluctuations of blood
pressure, which was managed effectively with Nitroglyc-
erine infusion. Histopathological examination revealedFigure 1 CT scan abdomen (coronal section) showing the
adrenal gland.adreno-cortical carcinoma (Mitotic rate 60/50 high power
field) with microscopic lymphovascular invasion and inva-
sion limited to the capsule and small vessel. There was
extensive tumor necrosis with hemorrhage and calcification
(Fig. 4). However, no microscopic features suggestive of
phaeochromocytoma seen on histopathology of adrenal
medulla. Postoperative period was uneventful and is on
follow-up for the last one year and is doing well.
3. Discussion
Adrenocortical carcinoma is itself a rare disease, of which
functional adrenocortical carcinoma accounts for 50%e79%
of cases [8]. Rapidly progressing Cushing’s syndrome with or
without virilization is the most frequent presentation [9].
Adrenocortical carcinoma can present with dysfunctional
uterine bleeding in women due to increased amounts of
androstenedione and estrogens [10]. However, adrenocor-
tical carcinoma presenting with features of pheochromo-
cytoma alone is a rare entity and it is rarest to have
features of both Cushing’s syndrome as well as pheochro-
mocytoma in the same patient with adrenal tumor. Despite
extensive PubMed search, no reports of the existence of an
adrenal tumor presenting with both features of Cushing’s
syndrome as well as pheochromocytoma has been found till
date.Figure 3 Specimen.
Figure 4 Histopathological report of the specimen
(40magnification; Haematoxylin and Eosin stain).
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A functional giant adrenocortical carcinoma with features
of both Cushing’s syndrome and pheochromocytoma is a
rare entity. Surgical extirpation is a good management
option for giant, resectable adrenocortical carcinoma.
Precise preoperative work-up and cautious pre-, peri- and
postoperative management for the functional component is
of utmost importance. A further long stringent follow-up
will throw light into the behavior of this entity.
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